French
DeutschFiclatuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6446H9954N1718O2026S46 |
| Molar mass | 145409.30 g·mol−1 |
  (what is this?) (verify) | |
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.[2]
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[3]
References
[edit]- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
- ^ Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. pp. 49–64 (57). doi:10.1007/978-3-030-55035-6_3. ISBN 978-3-030-55034-9. PMID 33725344. S2CID 232261340.
- ^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |